352 related articles for article (PubMed ID: 23760662)
41. Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
Besse B; Soria JC; Le Chevalier T
Ann Oncol; 2005 Jul; 16(7):997-8. PubMed ID: 15946975
[No Abstract] [Full Text] [Related]
42. Elevated frequencies of CD14
Xue G; Jiang M; Zhao R; Le A; Li J
Aging (Albany NY); 2021 Feb; 13(5):6236-6246. PubMed ID: 33640878
[TBL] [Abstract][Full Text] [Related]
43. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Cancer Res; 2010 Jun; 70(11):4335-45. PubMed ID: 20484028
[TBL] [Abstract][Full Text] [Related]
44. Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
Monnerat C; Le Chevalier T
Ann Oncol; 2006 May; 17 Suppl 5():v86-90. PubMed ID: 16807472
[TBL] [Abstract][Full Text] [Related]
45. Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
Zhang YM; Li YQ; Liu ZH; Liao XL; Liang R; Lin Y; Yuan CL; Liao SN; Liang CY; Li Q; Li LQ
Asian Pac J Cancer Prev; 2014; 15(8):3447-50. PubMed ID: 24870737
[TBL] [Abstract][Full Text] [Related]
46. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
[TBL] [Abstract][Full Text] [Related]
47. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Shi X; Yu XM; Zhang YP; Zhao J
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
[TBL] [Abstract][Full Text] [Related]
48. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ
Med Oncol; 2014 Jul; 31(7):70. PubMed ID: 24927957
[TBL] [Abstract][Full Text] [Related]
50. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
[TBL] [Abstract][Full Text] [Related]
51. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
West HL; Wakelee HA; Perry MC; Belt RJ; Chen R; Obasaju C
Ann Oncol; 2009 May; 20(5):850-6. PubMed ID: 19150937
[TBL] [Abstract][Full Text] [Related]
52. Pemetrexed in the treatment of non-small cell lung cancer.
Shepherd FA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):43-8. PubMed ID: 12571810
[TBL] [Abstract][Full Text] [Related]
53. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929
[TBL] [Abstract][Full Text] [Related]
54. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
[TBL] [Abstract][Full Text] [Related]
55. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
56. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H
Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116
[TBL] [Abstract][Full Text] [Related]
57. The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Sun JM; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Lee JS; Kim YW; Heo DS; Bang YJ
Lung Cancer; 2010 Jun; 68(3):427-32. PubMed ID: 19674811
[TBL] [Abstract][Full Text] [Related]
58. The CD14
Mengos AE; Gastineau DA; Gustafson MP
Front Immunol; 2019; 10():1147. PubMed ID: 31191529
[TBL] [Abstract][Full Text] [Related]
59. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
Novello S; Pimentel FL; Douillard JY; O'Brien M; von Pawel J; Eckardt J; Liepa AM; Simms L; Visseren-Grul C; Paz-Ares L
J Thorac Oncol; 2010 Oct; 5(10):1602-8. PubMed ID: 20808252
[TBL] [Abstract][Full Text] [Related]
60. High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.
Arrieta O; Villarreal-Garza C; Pachuca D; Michel Ortega RM; Martinez-Barrera L; Flores-Estrada D; Astorga A
Med Oncol; 2011 Mar; 28(1):300-6. PubMed ID: 20049560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
